Clinical Trial: Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma
Brief Summary:
Glaucoma is the second leading cause of blindness among seniors in Canada. It is often associated with an elevated intraocular pressure (IOP), but its exact mechanism is still largely unknown. Some studies have shown a link between glaucoma and changes in the amount of oxygen in the veins of the eye. The study aims to compare the amount of oxygen in ocular veins among three different groups using a spectrophotometer. This instrument is linked to a camera and can measure the quantity of oxygen in the veins using different characteristics of the blood inside.
The groups of the study are: patients without glaucoma, patients suspected of glaucoma and patients newly diagnosed with glaucoma. The drug the investigators are using, Travoprost 0.004%, will only be administered to the groups suspected or diagnosed with glaucoma. Travoprost 0.004% is already approved for use in Quebec and is part of standard care. Ten patients will be recruited into each group for a total of 30 patients in this study. All patients for the suspected or diagnosed groups will be recruited from the Jewish General Hospital. Subsequently all testing will be done at the École d'optométrie, Université de Montréal
Detailed Summary:
Sponsor: Université de Montréal
Current Primary Outcome: Blood Oxygenation [ Time Frame: 1 hour ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Université de Montréal
Dates:
Date Received: October 3, 2012
Date Started: October 2012
Date Completion:
Last Updated: June 16, 2016
Last Verified: June 2016